terfenadine has been researched along with Dermatitis, Allergic Contact in 3 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
Dermatitis, Allergic Contact: A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urabe, K | 1 |
| Nakahara, T | 1 |
| Moroi, Y | 1 |
| Morita, K | 1 |
| Furue, M | 1 |
| Massey, WA | 1 |
| Charlesworth, EN | 1 |
| Freidhoff, L | 1 |
| Cooper, P | 1 |
| Kagey-Sobotka, A | 1 |
| Lichtenstein, LM | 1 |
| Simons, FE | 1 |
| Johnston, L | 1 |
| Gu, X | 1 |
| Simons, KJ | 1 |
3 trials available for terfenadine and Dermatitis, Allergic Contact
| Article | Year |
|---|---|
Mite-antigen induced immediate reactions in atopic dermatitis are inhibited by daily administration of fexofenadine.
Topics: Administration, Oral; Adult; Animals; Antigens, Dermatophagoides; Dermatitis, Allergic Contact; Derm | 2003 |
Cutaneous IgE-mediated inflammatory lesion size is inhibited by an H1 antagonist (terfenadine) while mediator release is unaffected in vivo and in vitro.
Topics: Basophils; Dermatitis, Allergic Contact; Double-Blind Method; Histamine Release; Humans; Immunoglobu | 1993 |
Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast.
Topics: Acetates; Adult; Allergens; Cyclopropanes; Depression, Chemical; Dermatitis, Allergic Contact; Drug | 2001 |